← Back to Search

Androgen

Testosterone Treatment for Chronic Kidney Disease

Phase 2
Recruiting
Led By Sandeep Dhindsa, MD
Research Sponsored by St. Louis University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
eGFR 15-45 ml/min/1.73m2 by MDRD (Modification of Diet in Renal Disease) equation
Men between ages of 18-85 years of age
Must not have
Initiated iron replacement in the last 3 months
Untreated, severe obstructive sleep apnea
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights
All Individual Drugs Already Approved
No Placebo-Only Group

Summary

This trial is testing the effectiveness of a testosterone supplement in men with low testosterone and kidney disease.

Who is the study for?
Men aged 18-85 with low testosterone and chronic kidney disease (eGFR 15-45 ml/min/1.73m2) can join this trial. They should have symptoms like low sex drive, mood changes, or loss of muscle. Men on warfarin, those who've had recent heart issues or blood clots, or with untreated severe conditions are excluded.
What is being tested?
The study is testing Jatenzo Pill's effect on men with low testosterone and kidney disease to see if it improves their hormone levels and red blood cell count.
What are the potential side effects?
Possible side effects of Jatenzo may include increased risk of cardiovascular events like heart attack or stroke, liver problems, high blood pressure, enlarged prostate symptoms, potential for worsening sleep apnea, and changes in cholesterol.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My kidney function is moderately to severely reduced.
Select...
I am a man aged between 18 and 85.
Select...
My morning testosterone levels were below 300 ng/dl twice.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I started iron replacement therapy within the last 3 months.
Select...
I have severe sleep apnea that hasn't been treated.
Select...
My heart condition severely limits my daily activities.
Select...
I have had deep vein clots or lung clots more than once.
Select...
I have a history of prostate cancer.
Select...
I am being treated with drugs to help increase my red blood cells.
Select...
I am taking warfarin.
Select...
I have HIV or untreated hepatitis C.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Testosterone concentrations
Secondary study objectives
Hemoglobin
Lean mass
muscle strength
+1 more

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: treatmentExperimental Treatment1 Intervention
JATENZO daily for 6 months

Find a Location

Who is running the clinical trial?

St. Louis UniversityLead Sponsor
194 Previous Clinical Trials
41,003 Total Patients Enrolled
Clarus TherapeuticsUNKNOWN
2 Previous Clinical Trials
71 Total Patients Enrolled
Sandeep Dhindsa, MDPrincipal InvestigatorSt. Louis University
5 Previous Clinical Trials
39 Total Patients Enrolled

Media Library

Jatenzo (Androgen) Clinical Trial Eligibility Overview. Trial Name: NCT05249634 — Phase 2
Testicular Hypogonadism Research Study Groups: treatment
Testicular Hypogonadism Clinical Trial 2023: Jatenzo Highlights & Side Effects. Trial Name: NCT05249634 — Phase 2
Jatenzo (Androgen) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05249634 — Phase 2
Testicular Hypogonadism Patient Testimony for trial: Trial Name: NCT05249634 — Phase 2
~7 spots leftby Jun 2026